Hangzhou Diagens Biotechnology Co., Ltd. (HKG: 2526) announced that it has entered into a strategic cooperation agreement with Yongjiang Laboratory, a key digital intelligence innovation platform established by the Guangxi Zhuang Autonomous Region, to jointly advance the training, optimization, validation, and demonstration application of medical imaging large models in Guangxi. The agreement will be effective for a three‑year term starting from the date of execution.
Agreement Milestone
| Item | Detail |
|---|---|
| Parties | Hangzhou Diagens Biotechnology Co., Ltd. (HKG: 2526) and Yongjiang Laboratory |
| Agreement Type | Strategic cooperation agreement |
| Announcement Date | 6 Nov 2026 |
| Term | Three years from the date of execution |
| Scope | Training, optimization, validation, and demonstration application of medical imaging large models |
| Geographic Focus | Guangxi, with planned nationwide rollout and ASEAN market expansion |
| Financial Terms | Not disclosed |
Partnership Profile & Technology Stack
- Core Asset: The Group’s iMedImage medical imaging foundation model, combined with its intelligent software and hardware capabilities.
- Partner Strength: Yongjiang Laboratory’s regional coordination capabilities across healthcare institutions in Guangxi.
- Work Plan: Model training, on‑site optimization, multi‑center clinical validation, testing and evaluation, and demonstration applications.
- Target Scenarios: Alignment with clinical diagnosis, treatment, and medical insurance application scenarios across various tiers of healthcare institutions in Guangxi.
Industry Context – Medical Imaging AI
- Foundation Models: Large‑scale AI models trained on medical imaging data are increasingly deployed to support radiology and diagnostic workflows, improving consistency and throughput in clinical settings.
- Multi‑Center Validation: Clinical validation across multiple centers is the standard pathway for demonstrating the reliability and generalizability of AI diagnostic solutions before wider adoption.
- Regional Innovation Platforms: Provincial digital intelligence laboratories such as Yongjiang Laboratory serve as innovation hubs that coordinate AI adoption across regional healthcare systems.
Market Impact & Outlook
- Demonstration‑to‑Scale Pathway: Building upon operational results achieved in Guangxi’s benchmark demonstration hospitals and regional medical consortia, the two parties plan to promote these integrated solutions to healthcare and medical insurance systems nationwide.
- ASEAN Gateway Strategy: The partners intend to capitalize on Guangxi’s strategic geographic advantage as a gateway to the Association of Southeast Asian Nations (ASEAN) to explore medical technology cooperation and software and hardware product exports targeted at ASEAN markets.
- Strategic Positioning: The agreement extends Diagens’ footprint in AI‑enabled diagnostics, pairing its imaging foundation model with a government‑backed regional platform to accelerate real‑world deployment.
- Revenue Impact: No immediate financial contribution was disclosed; benefits are expected to accrue over the three‑year cooperation term.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the implementation of the cooperation agreement, clinical validation outcomes, nationwide rollout, and ASEAN market expansion plans. Actual results may differ due to risks including regulatory review of AI‑based medical software, clinical validation results, adoption by healthcare and medical insurance systems, and cross‑border commercialization dynamics.-Fineline Info & Tech
